user

Empagliflozin benefits in patients with heart failure and preserved ejection fraction

被引：0
|
作者：
机构：
来源：
Nature Medicine | 2022年 / 28卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Subgroup analysis of the EMPEROR-Preserved clinical trial of the glucose-lowering drug empagliflozin in chronic heart failure with left ventricular ejection fraction (LVEF) >40% found improved clinical outcomes in the cohort of patients with LVEF ≥50%. This is, to our knowledge, the first time a drug therapy has been unequivocally demonstrated to benefit this patient population.
引用
收藏
页码：2480 / 2481
页数：1
相关论文
共 50 条
  • [11] Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age
    Boehm, Michael
    Butler, Javed
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Abdin, Amr
    Mahfoud, Felix
    Brueckmann, Martina
    Gollop, Nicholas D.
    Iwata, Tomoko
    Ponikowski, Piotr
    Wanner, Christoph
    Zannad, Faiez
    Packer, Milton
    Anker, Stefan D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 80 (01) : 1 - 18
  • [12] Empagliflozin and Elderly Patients With Preserved Ejection Fraction Heart Failure Is Age Just a Number?*
    Sauer, Andrew J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 80 (01) : 19 - 21
  • [13] Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation
    Filippatos, Gerasimos
    Farmakis, Dimitrios
    Butler, Javed
    Zannad, Faiez
    Ferreira, Joao Pedro
    Ofstad, Anne Pernille
    Iwata, Tomoko
    Brueckmann, Martina
    Pocock, Stuart J.
    Packer, Milton
    Anker, Stefan D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (07) : 970 - 977
  • [14] Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction
    Butler, Javed
    Filippatos, Gerasimos
    Siddiqi, Tariq Jamal
    Ferreira, Joao Pedro
    Brueckmann, Martina
    Bocchi, Edimar
    Bohm, Michael
    Chopra, Vijay K.
    Giannetti, Nadia
    Iwata, Tomoko
    Januzzi, James L.
    Kaul, Sanjay
    Pina, Ileana L.
    Ponikowski, Piotr
    Rauch-Krohnert, Ursula
    Shah, Sanjiv J.
    Senni, Michele
    Sumin, Mikhail
    Verma, Subodh
    Zhang, Jian
    Pocock, Stuart J.
    Zannad, Faiez
    Packer, Milton
    Anker, Stefan D.
    CIRCULATION, 2022, 146 (14) : 1046 - 1055
  • [15] Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction EMPEROR-Preserved Trial
    Packer, Milton
    Butler, Javed
    Zannad, Faiez
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Carson, Peter
    Anand, Inder
    Doehner, Wolfram
    Haass, Markus
    Komajda, Michel
    Miller, Alan
    Pehrson, Steen
    Teerlink, John R.
    Schnaidt, Sven
    Zeller, Cordula
    Schnee, Janet M.
    Anker, Stefan D.
    CIRCULATION, 2021, 144 (16) : 1284 - 1294
  • [16] Design of the EMPERIAL-preserved trial of empagliflozin in patients with chronic heart failure with preserved ejection fraction
    Ponikowski, P.
    Abraham, W. T.
    Lindenfeld, J.
    Zeller, C.
    Macesic, H.
    Brueckmann, M.
    Salsali, A.
    Anker, S. D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 48 - 49
  • [17] EMPEROR-Preserved: Empagliflozin and Outcomes in Heart Failure with a Preserved Ejection Fraction and CKD
    Zannad, Faiez
    Kraus, Bettina J.
    Zeller, Cordula
    Pocock, Stuart
    Packer, Milton
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Anker, Stefan D.
    Butler, Javed
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : B3 - B3
  • [18] Projected clinical benefits of dapagliflozin in patients with heart failure with preserved ejection fraction
    Montero-Perez-Barquero, Manuel
    Escobar-Cervantes, Carlos
    Llacer, Pau
    Quiros-Lopez, Raul
    Trullas, Joan C.
    Cerqueiro, Jose M.
    Epelde-Gonzalo, Francisco
    Carrera-Izquierdo, Margarita
    Formiga, Francesc
    Gonzalez-Franco, Alvaro
    Casado-Cerrada, Jesus
    FUTURE CARDIOLOGY, 2023, 19 (06) : 333 - 342
  • [19] Design of the EMPERIAL trials of empagliflozin in patients with chronic heart failure with reduced or preserved ejection fraction
    Abraham, W. T.
    Anker, S. D.
    Salsali, A.
    Peil, B.
    Zeller, C.
    Brun, M.
    Macesic, H.
    Brueckmann, M.
    Lindenfeld, J.
    Ponikowski, P.
    DIABETOLOGIA, 2018, 61 : S323 - S324
  • [20] Empagliflozin in heart failure with preserved ejection fraction: first success in mission impossible
    Sciatti, Edoardo
    Gori, Mauro
    D'elia, Emilia
    Iacovoni, Attilio
    Senni, Michele
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24 : I153 - I159
12345